Cost-utility analysis of benmelstobart combined with anlotinib as first-line therapy for advanced clear cell renal cell carcinoma

GE Kunkun, ZHU Tongming, PAN Min, YI Jia, LI Wenqiang, SHEN Aizong

Chinese Journal of Hospital Pharmacy ›› 2026, Vol. 46 ›› Issue (10) : 1165-1172.

PDF(1144 KB)
PDF(1144 KB)
Chinese Journal of Hospital Pharmacy ›› 2026, Vol. 46 ›› Issue (10) : 1165-1172. DOI: 10.13286/j.1001-5213.2026.10.10
Drug and Clinical Practice

Cost-utility analysis of benmelstobart combined with anlotinib as first-line therapy for advanced clear cell renal cell carcinoma

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 46(10): 1165-1172 https://doi.org/10.13286/j.1001-5213.2026.10.10

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1144 KB)

Accesses

Citation

Detail
Sections
Recommended
Information
Governed by: China Association for Science and Technology
Sponsored by: Chinese Pharmaceutical Association
Published by: Editorial Office of Chinese Journal of Hospital Pharmacy
ISSN 1001-5213
CN 42-1204/R
Contact
Website Copyright © Chinese Journal of Hospital Pharmacy, All Rights Reserved.
Tel: 027-82836596
E-mail：pharmacy@vip.163.com
Wechat

/

〈 〉